Home / Companies / Novo Nordisk
Company family · HQ DK
Novo Nordisk: medicine shortages
As of 2 Nov 2026, 41 Novo Nordisk products have a reported shortage across 10 countries, covering 8 medicines.
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Long-run trend in Canada
Canada dashboardCanada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Semaglutide | 13 | 6 Jul 2023 | Other | 3/16 | |
| Liraglutide | 8 | 1 Jul 2023 | Not stated | 4/16 | |
| Insulin Aspart | 6 | 9 Apr 2025 | Not stated | 6/16 | |
| Coagulation Factor IX | 5 | 1 Jan 2026 | Not stated | 3/16 | |
| Coagulation Factor VIIa | 2 | 16 Jun 2025 | Manufacturing problem | 1/16 | |
| Insulin Aspart | 1 | 24 May 2024 | Other | 1/16 | |
| Insulin Detemir | 1 | not given | Not stated | 1/16 | |
| Somatropin | 1 | 14 Nov 2025 | Not stated | 4/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.